Table 1 Demographics and clinical data of patients with unresectable pancreatic cancer according to the study group
Group 1 | Group 2 | P value | |
|---|---|---|---|
n (%) | 86 (53.75%) | 74 (46.25%) | |
Age at diagnosis, median (range), years | 71.5 (43–100) | 69.5 (28–90) | 0.470c |
Gender (M/F) | 52/34 | 40/34 | 0.427 |
Tumor Stage (locally advanced/metastatic) | 16/70 | 18/56 | 0.440 |
Tumor location (head/body/tail) | 46/33/7 | 47/21/6 | 0.396 |
Tumor size, mean ± SD (cm) | 4.5 ± 1.5 | 4.1 ± 1.5 | 0.828d |
Patients with CA 19–9 > 1000 U/mL at diagnosisa | 40 (55.5%) | 33 (47.8%) | 0.401 |
Weight loss > 10% BW at diagnosis, n (%) | 47 (54.7%) | 48 (64.9%) | 0.220 |
Patients receiving palliative chemotherapy, n (%) | 40 (46.5%) | 53 (71.6%) | 0.001 |
Number of chemotherapy cycles, median (range)b | 3 (0.3–20) | 4 (1–40) | 0.004c |
Survival, median (range), days | 95.0 (33–768) | 189 (31–997) | < 0.001c |
Patients receiving PERT, n (%) | 0 (0%) | 49 (66.2%) | < 0.001 |